Introduction {#s2}
============

Tissue fibrosis, the excessive or dysregulated deposition of extracellular matrix (ECM) proteins, is a common pathophysiologic companion of a wide range of diseases. Although significant fibrosis is typically associated with organ dysfunction, its functional consequences are often context dependent and defy oversimplified views. In acute tissue injury, activation of a matrix-preserving fibrogenic program often reflects a reparative response, aiming at preserving the basic structural characteristics of the organ, thus preventing a catastrophic outcome. Whether fibrogenic activation has long-term effects on organ function is dependent on the regenerative capacity of the tissue and on the presence of regulatory mechanisms that suppress inappropriate or sustained activation of profibrotic signaling. In organs with very low regenerative capacity, such as the heart, formation of a fibrous scar is crucial to preserve structural integrity when large amounts of myocardium become necrotic. On the other hand, in tissues that can regenerate, injury-associated recruitment of fibrogenic interstitial cells is important for deposition of a specialized reparative ECM network that favors migration, activation, and differentiation of regenerative cell types. In these tissues, persistent, dysregulated, or overactive fibrogenic responses may impair regeneration and can cause dysfunction by perturbing the architecture of the structural units of the organ. Considering the close link between tissue repair and fibrosis, it is not surprising that mediators involved in healing responses have also been implicated in the pathogenesis of fibrosis-associated diseases.

The three TGF-β isoforms (TGF-β1, -β2, and --β3), are central regulators of cell differentiation, migration, proliferation, and gene expression and have been implicated in both reparative and fibrotic responses. The notion that TGF-βs mediate tissue fibrosis is supported by cell biological studies, animal model experiments, and clinical evidence. TGF-βs are key activators of fibroblasts, the central cellular effectors of fibrotic responses, and may also act by promoting a fibrogenic phenotype in immune and vascular cells. In animal models, TGF-βs are induced and activated in fibrotic tissues and have been implicated in the pathogenesis of fibrogenic responses in several different organs. TGF-β overexpression in various tissues induces marked fibrotic changes ([@bib173]; [@bib175]; [@bib159]). In human patients with fibrotic conditions, persistent TGF-β induction and activation is typically associated with the severity of fibrotic changes ([@bib25]) and may predict fibrosis progression ([@bib8]). Moreover, in patients with systemic sclerosis, TGF-β neutralization decreased fibrosis-associated biomarkers, supporting the involvement of TGF-β in human fibrotic conditions ([@bib150]). Despite the strong evidence-based link between TGF-β and fibrotic conditions, therapeutic implementation of anti--TGF-β approaches is hampered by the pleiotropic, multifunctional, and context-dependent actions of the growth factor.

This review deals with the role of TGF-β isoforms in regulation of fibrotic responses, discussing the biology of TGF-β activation, the cellular mechanisms responsible for fibrogenic TGF-β effects, the downstream molecular cascades, and the challenges of therapeutic implementation of strategies targeting the TGF-β system in fibrotic conditions.

Induction and activation of TGF-β in tissue injury and fibrosis {#s3}
===============================================================

Induction and spatial localization of active TGF-β: The "profibrotic cellular niche" {#s4}
------------------------------------------------------------------------------------

TGF-β signaling cascades are consistently activated in fibrotic tissues, regardless of the etiology of the initial injury. Stimulation of TGF-β signaling not only requires de novo synthesis and secretion of TGF-β isoforms, but also involves spatially restricted generation of active TGF-βs from latent stores. Several distinct pathways induce TGF-β isoform expression in fibrotic tissues. Neurohumoral mediators, such as angiotensin II and norepinephrine, are released in many fibrotic conditions and induce TGF-β transcription and subsequent secretion of latent TGF-βs by many different cell types ([@bib22]; [@bib20]). Oxidative stress, Toll-like receptor signaling, and proinflammatory cytokines (such as IL-1β, TNF-α, and IL-6) can also stimulate transcription of TGF-β isoforms in fibrotic tissues ([@bib185]; [@bib100]; [@bib187]). The cellular source of latent TGF-βs in fibrotic areas remains poorly defined, as several different cell types have been implicated. Disruption of pathways involved in macrophage recruitment reduced TGF-β synthesis and attenuated fibrosis in models of acute and chronic fibrotic injury ([@bib39]; [@bib52]; [@bib210]), suggesting that macrophages are a major source of TGF-β ([@bib79]). In contrast, in models of ischemic and obstructive renal injury, myeloid cell--specific deletion of TGF-β1 did not affect kidney fibrosis ([@bib76]), as other cell types (such as epithelial cells) appeared to serve as a major source of TGF-βs ([@bib30]). Platelets ([@bib116]), T cell subsets ([@bib26]; [@bib105]; [@bib190]), fibroblasts ([@bib134]), and mast cells ([@bib60]) have also been suggested to represent important sources of TGF-β in various pathophysiological models of tissue fibrosis. Moreover, the ECM contains significant stores of latent TGF-β (bound to proteoglycans, collagens, or fibronectin) that can be released and activated following injury through protease-dependent mechanisms ([@bib47]), without the requirement for de novo synthesis. The cellular origin of TGF-β in various fibrotic diseases may reflect the specific cell biological alterations that characterize each pathological condition.

Because TGF-β is secreted in a latent form, generation of bioactive TGF-β is the major mechanism regulating TGF-β actions in fibrotic tissues. Spatially restricted release of active TGF-β that binds to fibroblast TGF-β receptors (TβRs) to activate profibrotic signaling may involve formation of a profibrotic cellular niche comprising immune cells and fibroblasts. Cell biological experiments suggested that macrophages and fibroblasts may cooperate to activate a TGF-β--driven fibrogenic program. Macrophages produce large amounts of latent TGF-βs; cadherin 11--mediated adhesion of fibroblasts to macrophages may be required to activate TGF-β stores in the proximity of the fibroblasts ([@bib106]), making the growth factor available for receptor binding. The profibrotic cellular environment required for TGF-β secretion and activation may also involve other immune cell types, platelets, or vascular cells, depending on the pathophysiologic context ([Fig. 1](#fig1){ref-type="fig"}).

![**TGF-β secretion and activation in fibrotic tissues.** Many different cell types, including macrophages, lymphocytes, epithelial cells, fibroblasts, pericytes (P), endothelial cells, and platelets (Plt), can produce and secrete TGF-β isoforms in sites of injury. The specific cellular origins of TGF-βs are dependent on the type of injury and on the cellular composition of the affected organ. TGF-βs are secreted in a latent form, typically as the tripartite LLC, comprised of mature TGF-β, its propeptide called LAP, and LTBP. Liberation of mature TGF-β from the latent form involves effects of proteases, integrin (ITG)-mediated actions, and contributions of specialized ECM proteins that may serve to localize the activation process or interact with LAP to release the active molecule. Active TGF-β binds to its receptors on the surface of the target cell, initiating signaling responses that promote fibrosis. SLC, small latent complex.](JEM_20190103_Fig1){#fig1}

Molecular mechanisms of TGF-β activation {#s5}
----------------------------------------

TGF-βs are synthesized as homodimeric proproteins that contain both the C-terminal growth factor (mature TGF-β) and its propeptide (referred to as latency-associated peptide \[LAP\]). In the endoplasmic reticulum, the proprotein is linked to another protein, latent TGF-β binding protein (LTBP), through a pair of disulfide bonds between LTBP and LAP. The complex is subsequently transported to the Golgi, where LAP is cleaved from the mature growth factor through furin-mediated actions; however, TGF-β and LAP remain tightly bound through noncovalent interactions. TGF-β is secreted by the cells, either as the tripartite large latent complex (LLC) that consists of mature TGF-β, LAP, and LTBP or as the TGF-β/LAP complex, known as the small latent complex ([@bib151]). Binding of LAP to mature TGF-β confers latency, preventing binding of the growth factor to its receptors ([@bib7]). On the other hand, LTBP is important for effective secretion of the LLC, while localizing the secreted growth factor to the ECM. Injury increases the local extracellular stores of latent TGF-βs through de novo synthesis and secretion and also stimulates a wide range of molecular signals that mediate release of mature bioactive TGF-βs from the latent complex, thus serving as "TGF-β activators" ([Fig. 1](#fig1){ref-type="fig"}). Depending on contextual factors, the type of injury, and the cell biological composition of the tissue, several different pathways may play a role in TGF-β activation in fibrotic tissues. First, a number of proteases, including calpains, cathepsins, serine proteases, matrix metalloproteinases (MMPs), and members of the ADAMTS (a disintegrin and metalloproteinase with thrombospondin motifs) family, are capable of activating TGF-β in vitro and may be implicated in TGF-β activation in fibrotic lesions in vivo ([@bib170]; [@bib19]; [@bib18]; [@bib44]; [@bib137]; [@bib84]; [@bib206]). Considering the promiscuity of these proteases, which are capable of interacting with numerous substrates, the relative significance of their TGF-β--activating effects remains poorly understood. Second, cell-surface integrins are well-documented activators of latent TGF-β. Robust experimental evidence suggests that αv integrins trigger spatially restricted TGF-β activation in fibrotic tissues ([@bib126]; [@bib67]) through protease-dependent or -independent actions. Protease-mediated TGF-β activation requires binding of the integrin to LAP and recruitment of MMP14, which releases TGF-β through proteolytic actions ([@bib125]). Nonproteolytic activation may involve tractional forces exerted by the actin cytoskeleton that induce conformational changes of the LLC, leading to presentation of active TGF-β to its receptors ([@bib197]; [@bib108]; [@bib198]). In vivo, mechanosensitive activation of TGF-β in lung fibrosis has been suggested to involve αv integrins ([@bib54]). Third, specialized matrix proteins, such as fibronectin isoforms, fibulin-1c, and thrombospondin (TSP)-1, have been implicated in activation of TGF-β in fibrotic tissues. The ED-A splice variant of fibronectin (ED-A Fn) is markedly up-regulated in fibrotic tissues and contributes to TGF-β activation by immobilizing LTBPs into the matrix, thus localizing activatable TGF-β in the area of injury ([@bib89]; [@bib169]). TSP-1, a multidomain matricellular protein with a wide range of actions, is markedly induced in fibrotic tissues ([@bib50]) and has been suggested to act as a crucial activator of TGF-β in some ([@bib131]; [@bib14]; [@bib33]; [@bib202]), but not all, models of tissue fibrosis ([@bib46]; [@bib59]). The TGF-β--activating effects of TSP-1 are mediated through an interaction with LAP that prevents new formation of LAP:TGF-β latent complexes, thus increasing the availability of mature TGF-β that can be bound to its receptors ([@bib165]; [@bib148]). Fibulin-1c has also been suggested to activate TGF-β in fibrotic lungs through an interaction with LTBP1 ([@bib103]). Finally, TGF-β can be activated through exposure to specific physical or chemical conditions, such as low pH, heat, radiation, shear stress, and generation of reactive oxygen species ([@bib151]). Some of these conditions may be relevant to the fibrotic process. For example, the acidic environment in ischemic tissues due to the release of lactic acid may contribute to TGF-β activation in fibrosis caused by chronic ischemia (such as chronic ischemic cardiomyopathy). Exposure of tissue to ionizing radiation is also typically associated with stimulation of TGF-β signaling cascades that may reflect radiation-induced generation of active TGF-β from latent stores.

The relative role of TGF-β isoforms in fibrotic conditions {#s6}
==========================================================

Although all three TGF-β isoforms are up-regulated in fibrotic tissues, they typically exhibit distinct temporal expression patterns in relation to the causative injurious insult. In models of acute cutaneous and cardiac injury, TGF-β1 is induced early, whereas TGF-β3 expression levels peak much later ([@bib53]; [@bib38]). Distinct patterns of up-regulation may be due to differential isoform expression in various cell types that sequentially infiltrate injured tissues ([@bib191]; [@bib31]) or may reflect isoform-specific effects of stimuli that induce TGF-β transcription or release ([@bib158]). In vitro, all three isoforms have been reported to exert similar fibrogenic actions, activating Smad-dependent signaling, stimulating ECM protein synthesis ([@bib83]; [@bib211]; [@bib156]), and promoting fibroblast-to-myofibroblast conversion ([@bib168]). In vivo studies investigating the relative role of the three isoforms in fibrotic responses are limited and have produced controversial and often contradictory results. Some investigations have suggested that upon local application in tissues, all three TGF-β isoforms exert similar profibrotic actions ([@bib32]). Overexpression studies showed that TGF-β3--induced fibrosis has similar characteristics but is less severe in comparison to the pronounced fibrogenic actions of TGF-β1 ([@bib11]). In contrast, other experimental studies suggested that TGF-β3 may be a negative regulator of the fibrotic response ([@bib168]; [@bib136]) that may accelerate wound healing without promoting formation of a scar ([@bib107]). The reparative actions of TGF-β3 were attributed to its effects on migratory cellular responses ([@bib13]) and led to the development of recombinant human TGF-β3 as a potential inhibitor of hypertrophic scarring in excisional wounds ([@bib102]). Unfortunately, the failure of phase III clinical trials using TGF-β3 to improve scar quality generated more controversy regarding the effects of this isoform in fibrotic tissues. Isoform-specific in vivo effects may be related to their distinct spatial and temporal patterns of localization (resulting in predominant isoform-specific stimulation of various cell types), to distinct patterns of binding to ECM components (that may affect their availability and binding to cellular receptors), to distinct mechanisms of activation for each isoform, or to different receptor binding properties (for example, TGF-β2 exhibits low affinity for TβRII and may require coreceptors to assemble a stable signaling complex; [@bib71]). Robust genetic studies examining the effects of conditional deletion of each isoform in models of fibrosis have not been performed.

Cell biological targets of TGF-βs in fibrosis {#s7}
=============================================

As the main matrix-producing cells, fibroblasts are the central effectors of fibrosis and are major targets of TGF-βs in fibrotic conditions. However, TGF-β--mediated fibrosis may also involve activation of a fibrogenic phenotype in other cell types, including immune cells and vascular cells ([Fig. 2](#fig2){ref-type="fig"}).

![**The cellular targets of TGF-βs in tissue fibrosis.** Although resident fibroblasts are major cellular targets of TGF-βs in fibrotic conditions, some TGF-β--mediated fibrogenic effects may involve actions on other cell types, including myeloid fibroblast progenitors (My), macrophages, epithelial cells, pericytes, and endothelial cells. TGF-β is a central mediator in fibroblast-to-myofibroblast conversion and promotes a matrix-preserving phenotype, associated with secretion of ECM proteins and tissue inhibitors of metalloproteinases (TIMPs). Some studies have suggested that expansion of myofibroblasts in fibrotic tissues may also involve TGF-β--mediated conversion of circulating progenitors, epithelial cells, pericytes, and endothelial cells into fibroblasts. TGF-β may also exert indirect activating effects on fibroblasts by promoting secretion of fibrogenic cytokines, growth factors, and matricellular proteins by macrophages, vascular cells, and epithelial cells.](JEM_20190103_Fig2){#fig2}

Effects of TGF-βs on fibroblasts {#s8}
--------------------------------

Abundant experimental evidence supports the concept that TGF-β--driven tissue fibrosis involves direct effects on fibroblasts. In mouse models of fibrosis, fibroblast-specific deletion of TβRs markedly attenuated the fibrotic response ([@bib85]; [@bib194]). The fibrogenic actions of TGF-β are attributed predominantly to its critical role in myofibroblast phenoconversion, the hallmark of tissue fibrosis. Much like fibroblasts, myofibroblasts exhibit mesenchymal features, such as the abundance of vimentin-positive intermediate filaments ([@bib73]). The main discriminating feature of myofibroblasts is the presence of a rich network of actin-myosin bundles that connect to the surrounding matrix through focal adhesions and may play a role in scar contraction. In response to TGF-β stimulation, these contractile fibers are decorated with α-smooth muscle actin, the most widely used marker of mature myofibroblasts in tissues ([@bib58]; [@bib72]; [@bib179]; [@bib171]). Moreover, compared with resident fibroblasts in normal tissues, activated myofibroblasts in fibrotic lesions exhibit higher expression of structural collagens and may synthesize a wide range of matricellular proteins, cytokines, and growth factors ([@bib90]). The molecular links between acquisition of a contractile phenotype and increased matrix synthetic capacity in myofibroblasts remain unknown. Metabolic reprogramming of fibroblasts in response to TGF-β stimulation may be implicated in activation of a matrix-synthetic program and myofibroblast conversion. Recent studies have suggested that TGF-β--driven activation of fibroblasts may involve accentuation of metabolic activity. TGF-β stimulation induces metabolic reprogramming in fibroblasts and accentuates glycolytic pathways ([@bib172]), inducing expression and activation of hexokinase-2 ([@bib207]). Hexokinase-2 activation has been shown to stimulate myofibroblast conversion while also inducing ECM gene synthesis ([@bib207]).

Although TGF-β is crucial for fibroblast-to-myofibroblast conversion in fibrotic tissues, it has been suggested that some of its fibrogenic effects may also involve myofibroblast differentiation of other cell types (such as epithelial cells, pericytes, endothelial cells, or circulating hematopoietic cells). However, the relative contribution of these cell types in myofibroblast populations in fibrotic lesions remains controversial and likely depends on contextual factors.

In addition to its central role in myofibroblast conversion, TGF-β exerts a wide range of actions on fibroblasts, modulating proliferation, migration, survival, and gene expression. These actions have pronounced effects on ECM remodeling. TGF-β potently stimulates gene transcription of structural collagens and may be implicated in posttranslational modification of collagen by increasing its stability through enhanced cross-linking ([@bib111]; [@bib143]; [@bib16]). Moreover, TGF-β exerts matrix-preserving actions by suppressing the activity of matrix-degrading proteases, through the induction of protease inhibitors such as plasminogen activator inhibitor 1 and tissue inhibitors of metalloproteinases ([@bib164]; [@bib110]). The effects of TGF-β on fibroblast proliferation are inconsistent: many studies have reported antiproliferative actions ([@bib146]; [@bib40]), while other investigations suggest that TGF-β may enhance fibroblast proliferation ([@bib114]; [@bib86]). The conflicting data may reflect the context-dependent actions of TGF-βs (which typically depend on the presence of other interacting mediators, the state of differentiation of the cells, the ECM environment, etc.) and the functional and phenotypic heterogeneity of fibroblast populations ([@bib115]).

Effects of TGF-β on immune cells may contribute to the pathogenesis of fibrosis {#s9}
-------------------------------------------------------------------------------

Macrophages are viewed as critical regulators of fibrotic responses, acting predominantly by secreting cytokines, growth factors, and matricellular proteins that modulate fibroblast function, and through the release of proteases that contribute to ECM remodeling ([@bib200]). Macrophages are highly responsive to TGF-β stimulation, exhibiting reduced H~2~O~2~ releasing capacity ([@bib182]) and attenuated proinflammatory gene synthesis ([@bib27]). To what extent the fibrogenic actions of TGF-β are dependent on macrophage-derived profibrotic signals remains unclear. In a model of renal fibrosis, myeloid cell--specific disruption of TGF-β signaling attenuated fibrosis ([@bib30]). Several mechanisms may contribute to the fibrogenic actions of TGF-β--stimulated macrophages. First, TGF-β1 is a potent chemotactic factor for monocytes and promotes migration at femtomolar concentrations ([@bib189]). Thus, TGF-β may promote fibrosis simply by increasing the density of macrophages in injured tissues. Second, TGF-β may enhance expression of profibrotic cytokines by activated macrophages, thus indirectly stimulating tissue fibroblast activation ([@bib29]; [@bib27]). Whether TGF-β targets a specific subset of "fibrogenic" macrophages with distinct functional properties and trafficking patterns remains unknown. Third, TGF-β may stimulate synthesis of macrophage-derived matricellular proteins (such as osteopontin and SPARC \[secreted protein acidic and rich in cysteine\]; [@bib112]) that may bind to the structural matrix transducing profibrotic signals in cardiac fibroblasts. Fourth, macrophages may act by accentuating TGF-β activation in the fibrotic area, through secretion of TGF-β--activating mediators ([@bib117]), or through expression of integrins ([@bib92]). Some studies have suggested that TGF-βs may stimulate phenotypic conversion of myeloid cells to fibroblasts ([@bib192]). Although investigations in both animal models and human patients have identified "fibrocytes" as mesenchymal cells derived from circulating monocyte precursors ([@bib1]; [@bib145]), their contribution to the fibrotic process remains poorly documented. Several robust investigations using bone marrow chimeras and lineage-tracing approaches failed to demonstrate significant contributions of myeloid cells to fibroblast populations in mouse models of fibrosis ([@bib81]; [@bib121]).

Lymphocytes have been implicated in regulation of fibrotic conditions ([@bib134]) and are highly responsive to TGF-β ([@bib181]). Experimental studies suggest that TGF-βs have important, but context-dependent, effects on proliferation, differentiation, activation, and function of lymphocyte subsets. TGF-βs potently down-regulate T helper cell 1 and 2 differentiation ([@bib62], [@bib61]) and regulate generation, maintenance, and function of regulatory T cell populations ([@bib160]). To what extent the actions of TGF-β on lymphocytes mediate fibrotic responses remains unknown, as robust in vivo studies are lacking.

Vascular cells as targets of TGF-β in fibrotic tissues {#s10}
------------------------------------------------------

The high prevalence of perivascular fibrosis in a wide range of conditions affecting several different organs (including the heart, lung, and liver; [@bib24]; [@bib51]), and the common localization of TGF-βs in the microvasculature of fibrotic lesions ([@bib77]), suggest a potential role for TGF-β--driven modulation of vascular cells in the pathogenesis of fibrotic diseases. Endothelial cells and mural cells may acquire a fibrogenic phenotype in response to TGF-β, expressing ECM proteins or secreting fibroblast-activating mediators. Moreover, both endothelial and vascular mural cells may convert to fibroblasts in response to TGF-β, thus expanding the population of matrix-producing cells in fibrotic tissues.

### Endothelial cells {#s11}

Constitutive endothelial cell--specific activation of TGF-β signaling in transgenic mice triggered cutaneous, pulmonary, and microvascular fibrosis, associated with endothelial-to-mesenchymal transition (EndMT) and myofibroblast infiltration ([@bib195]). These findings suggest that activation of endothelial cells by TGF-β is sufficient to induce diffuse fibrotic changes. However, the role of endothelial cells as critical targets of TGF-βs in common fibrotic conditions is less convincingly documented. Several lines of evidence suggest that TGF-β--driven EndMT may be a critical fibrogenic mechanism in fibrotic conditions ([@bib141]). In models of renal fibrosis, endothelial cell--specific reduction in TβRII levels attenuated fibrotic remodeling, inhibiting EndMT ([@bib201]). In a model of cardiac fibrosis, lineage-tracing strategies and cell biological experiments suggested that TGF-β--stimulated endothelial cells undergo fibroblast conversion, contributing to the fibrotic response ([@bib214]). In hepatic fibrosis, a relatively small population of hepatic endothelial cells underwent TGF-β--induced EndMT and contributed to the fibrotic process ([@bib149]). In a model of bleomycin-induced pulmonary fibrosis, a significant number of endothelial-derived fibroblasts were identified ([@bib68]). In contrast, other investigations using lineage-tracing approaches found very low numbers of endothelial cell--derived fibroblasts in fibrotic hearts ([@bib81]; [@bib122]; [@bib6]). Conflicting published data may reflect, at least in part, the methodological limitations of lineage-tracing experiments. For example, the use of nonspecific endothelial Cre drivers in some studies and the challenges in labeling of fibroblasts due to the lack of specific markers may limit the reliability of identification of endothelial cell--derived fibroblasts. Moreover, endothelial cells are heterogeneous and may exhibit site-specific responses to the effects of fibrogenic agents, such as TGF-β. In addition to its effects on EndMT, TGF-β may transduce fibrogenic signals through induction of endothelial-derived mediators that stimulate perivascular fibroblasts.

### Mural cells {#s12}

Studies in both animal models of fibrosis and human patients suggested that activated myofibroblasts in fibrotic lesions may be derived, at least in part, from activated perivascular cells ([@bib162]; [@bib93]; [@bib42]). In vitro, TGF-βs promote a fibrogenic phenotype in pericytes ([@bib147]). In vivo, adenoviral overexpression of TGF-β1 in the skin resulted in expansion of connective tissue cells with characteristics that suggested pericyte origin ([@bib153]). However, to what extent TGF-β--mediated fibrosis is due to fibrogenic transformation of pericytes in vivo remains unclear. Robust genetic studies have not been performed.

### Epithelial cells {#s13}

TGF-β stimulates a fibrogenic phenotype in epithelial cells, either directly by promoting epithelial-to-mesenchymal transition (EMT) and subsequent differentiation to a myofibroblast phenotype ([@bib215]), or indirectly by stimulating secretion of fibroblast-activating mediators. Thus, in tissues with significant epithelial cell populations, TGF-β--mediated fibrosis may involve epithelial cell activation. TGF-β--driven EMT has been implicated in the pathogenesis of fibrosis in several different organs, including the kidney ([@bib161]), liver ([@bib157]), and lung ([@bib196]). Epithelial cells undergoing EMT lose their junctions and apical-basal polarity and exhibit down-regulation of epithelial marker proteins such as E-cadherin and cytokeratins, while up-regulating mesenchymal markers (such as vimentin) acquire a migratory phenotype ([@bib97]). Although in some studies a significant proportion of activated myofibroblasts in fibrotic lesions were derived from epithelial cells ([@bib88]), other investigations failed to demonstrate evidence of EMT in fibrotic conditions ([@bib152]). In addition to the fibrogenic effects of EMT, TGF-β--stimulated epithelial cells have been demonstrated to release profibrotic mediators, such as TGF-βs and platelet-derived growth factor-BB ([@bib199]), that may activate fibroblasts.

The molecular signals involved in TGF-β--mediated fibrosis {#s14}
==========================================================

Each member of the TGF-β superfamily signals through a characteristic combination of type I and type II TβRs. ([@bib109]; [@bib71]). There are seven human type I receptors, termed activin-like receptor kinase (ALK) 1--7, and five type II receptors. All three TGF-β isoforms transduce signaling through a single type II receptor (TβRII). Binding of TGF-βs to the constitutively active TβRII recruits and transphosphorylates the type I receptor kinases. In most cell types, TGF-βs activate the ubiquitously expressed type I receptor ALK5 ([@bib144]). In endothelial cells, TGF-βs exert distinct effects through a second type I TβR, ALK1 ([@bib64]). Although some studies have suggested that TGF-βs may transduce ALK-1 signaling in other cell types, including fibroblasts ([@bib216]) and macrophages ([@bib135]), the role of these pathways is unclear. Subsequently, the activated type I receptors phosphorylate intracellular transcriptional regulators, the receptor-activated Smads (R-Smads): ALK5 activates Smad2 and 3, whereas ALK1 triggers activation of Smad1, 5, and 8. Activated R-Smads form complexes with the common Smad, Smad4, and translocate to the nucleus, where they modulate gene transcription ([@bib48]). In addition to activation of canonical Smad-dependent cascade, TGF-βs can signal by activating MAPK family responses, including ERK, p38 MAPK, and JNK signaling. TGF-β effects on MAPK signaling may modulate Smad-dependent pathways or exert Smad-independent actions ([@bib56]; [@bib94]; [@bib57]; [@bib208]; [@bib167]). Moreover, TGF-β can also activate phosphoinositide 3-kinase/Akt and Rho GTPase pathways and cooperate with Wnt and Notch signaling cascades ([@bib37]). The complexity of TGF-β signaling and the multiple interactions between TGF-β cascades and other pathways account, at least in part, for the context-dependent in vivo effects of the growth factor.

Which signaling cascades are responsible for the fibrogenic actions of TGF-βs ([Fig. 3](#fig3){ref-type="fig"})? There is ample experimental evidence to support the role of the ALK5/Smad3 axis in the pathogenesis of fibrosis in many different tissues. In animal models, pharmacologic inhibition of ALK5 attenuated fibrotic remodeling of the lung ([@bib17]), liver ([@bib35]), kidney ([@bib120]), heart ([@bib45]), intestine ([@bib113]), vasculature ([@bib55]), and bone marrow ([@bib212]). In fibroblasts, the potent fibrogenic actions of TGF-β/ALK5 signaling are predominantly mediated through activation of Smad3 ([@bib217]; [@bib49]; [@bib161]; [@bib21]; [@bib40]; [@bib85]). In contrast, despite extensive evidence suggesting effects of Smad2 signaling in regulating fibroblast phenotype in vitro, the in vivo role of Smad2 seems more limited, and fibroblast or myofibroblast-specific targeting did not significantly affect fibrotic remodeling in models of cardiac injury ([@bib85]; [@bib74]).

![**TGF-β signaling pathways in tissue fibrosis.** TGF-β stimulates a matrix-preserving transcriptional program in fibroblasts by activating Smad-dependent and non-Smad pathways. TGF-βs bind to TβR complexes, comprising a single type II receptor (TβRII) and two forms of type I receptors (ALK5 or ALK1). ALK5 activates Smad2/3, whereas ALK1 activates Smad1/5/8. Although the role of the TβRII--ALK5--Smad2/3 axis in fibrosis is relatively well established, the potential significance of ALK1-Smad1/5/8 remains unclear. TGF-β--mediated activation of non-Smad cascades may also contribute to the fibrotic response. R-Smads exhibit an extensive network of interactions with non-Smad pathways. Fibrogenic TGF-β signaling is also modulated through accessory receptors, such as endoglin, betaglycan, and BAMBI. The complexity of TGF-β signaling pathways, the extensive cross-talk with other signaling networks, and the variable expression of coreceptors depending on the differentiation state of the cells and the microenvironment may explain the context-specific in vivo actions of TGF-βs.](JEM_20190103_Fig3){#fig3}

Although there is broad consensus regarding the critical role of the TβRII/ALK5/Smad3 axis in TGF-β--driven tissue fibrosis, alternative noncanonical TGF-β--mediated pathways have also been implicated and may contribute to the fibrotic response by activating distinct phenotypic and functional profiles in tissue fibroblasts. The potential role of ALK1/Smad1/5 signaling in fibrotic conditions remains poorly documented. In a mouse model of scleroderma-like fibrosis due to forced expression of ALK5, activation of a fibrogenic transcriptional program was dependent on Smad1 and Erk1/2, and not on Smad2/3 ([@bib140]), suggesting that an ALK1/Smad1 pathway may be critically involved in certain fibrotic conditions. In contrast, in other studies, partial loss of ALK1 enhanced fibroblast-mediated matrix synthesis ([@bib129]), and ALK1^+/−^ mice exhibited increased fibrosis in experimental models of renal ([@bib127]) and cardiac ([@bib124]) injury. In the absence of fibroblast-specific targeting experiments, and considering the likely effects of Smad1 on endothelial cells and other cell types, these findings are difficult to interpret.

Moreover, several distinct TGF-β--activated Smad-independent pathways have been implicated in the pathogenesis of fibrosis in various tissues. Both in vitro and in vivo findings have suggested that p38 MAPK may play a role in the pathogenesis of renal fibrosis, acting downstream of TGF-β ([@bib176]). In models of cardiac injury, fibroblast-specific loss of p38 MAPK attenuated fibrotic and hypertrophic remodeling ([@bib119]; [@bib12]). Other studies have suggested that the MAPK kinase kinase (MAPKKK) TGF-activated kinase (TAK1) stimulates a matrix-synthetic fibroblast phenotype in vitro ([@bib138]) and in vivo ([@bib66]), presumably acting upstream of MAPKs. It should be emphasized that a diverse range of signals, not limited to TGF-βs, may converge on MAPKs to activate fibroblasts. Nonspecific pharmacologic inhibition experiments have also implicated the nonreceptor tyrosine kinase c-Abl kinase in TGF-β--mediated renal ([@bib193]) and pulmonary ([@bib34]) fibrosis.

In vitro, Smad-mediated signaling and TGF-β--induced non-Smad pathways are often interconnected. Smad signaling exhibits broad interactions with non-Smad pathways that regulate fibrotic responses, such as MAPKs ([@bib101]; [@bib41]), the Wnt/β-catenin axis ([@bib15]), and Notch cascades ([@bib9]). The in vivo significance of interactions between Smad-dependent and non-Smad pathways in mediating the fibrogenic actions of TGF-βs remains poorly understood.

The role of coreceptors in regulating TGF-β--mediated fibrotic responses {#s15}
------------------------------------------------------------------------

Profibrotic TGF-β signaling is modulated through interactions between TβRs and "accessory receptors," such as betaglycan and endoglin ([@bib71]). The transmembrane glycoprotein betaglycan can either activate or inhibit TGF-β signaling responses, depending on its expression levels and contextual factors. Some in vitro studies have demonstrated direct activating effects of betaglycan on TGF-β signaling cascades ([@bib209]). In other investigations, betaglycan was found to bind to TβRI and TβRII, preventing assembly of the signaling complex and inhibiting Smad-dependent cascades ([@bib178]). The role of betaglycan in fibrotic conditions is poorly understood. Limited in vitro and in vivo evidence suggests that betaglycan may inhibit fibroblast activation ([@bib4]; [@bib177]). Moreover, soluble betaglycan has been proposed as an antifibrotic strategy that may act by inhibiting binding of TGF-β to type I and type II receptors ([@bib104]). Other studies in lung fibroblasts demonstrated that betaglycan may act as a "switch" that blunts ALK5/Smad2/3 signaling and promotes an ALK1/Smad1/5 response ([@bib166]). However, the potential in vivo significance of the switch function of betaglycan remains unclear.

Endoglin acts as an accessory protein for TGF-β signaling predominantly in endothelial cells, negatively regulating ALK5-Smad2/3 responses, while enhancing ALK1-Smad1/5/8 signaling ([@bib99]). Endoglin expression is up-regulated in activated fibroblasts in many different fibrotic conditions ([@bib98]; [@bib155]); increased expression may reflect, at least in part, neurohumoral activation ([@bib28]). Studies on the role of endoglin in tissue fibrosis have produced conflicting results, suggesting both profibrotic ([@bib82]) and antifibrotic ([@bib154]; [@bib142]) effects. The conflicting findings may reflect the use of global loss- or gain-of-function approaches in fibrotic conditions with distinct cell biological responses and the different roles of the short and long endoglin isoforms ([@bib128]).

Although betaglycan and endoglin are the best-studied TGF-β coreceptors, a growing list of transmembrane molecules (such as CD44, neuropilin-1, polycystin-1, and BAMBI \[bone morphogenetic protein and activin membrane-bound inhibitor\]; [@bib183]; [@bib75]; [@bib184]) have been suggested to modulate TGF-β responses in fibrotic conditions and may account, at least in part, for the context-dependent actions of TGF-βs in vivo. Many of these coreceptors do not act exclusively on TGF-β signaling cascades, but also modulate responses of other growth factors. For example, neuropilin-1 has been suggested to promote TGF-β signaling in hepatic stellate cells, accentuating liver fibrosis ([@bib23]), but is also prominently involved in vascular endothelial growth factor signaling.

TGF-β--inducible mediators involved in tissue fibrosis {#s16}
------------------------------------------------------

At least some of the profibrotic effects of TGF-β may not reflect direct actions of the growth factor, but may be mediated through secretion of other fibrogenic effectors. A recent study identified TGF-β--induced IL-11 expression as a critical fibrogenic signal that acts through Erk activation ([@bib163]). Other investigations have suggested that TGF-β--mediated myofibroblast conversion may involve up-regulation of the sheddase ADAM10 (a disintegrin and metalloproteinase domain-containing protein 10) and subsequent ephrin B2 shedding, leading to activation of soluble ephrin B2/EphB receptor signaling ([@bib96]). The matricellular protein CCN2 (also known as connective tissue growth factor) was suggested as a key TGF-β--inducible signal, responsible for myofibroblast conversion and fibrogenic signaling ([@bib43]; [@bib2]). In vivo, a role for CCN2 in potentiating TGF-β--induced fibrosis was proposed based on experiments demonstrating the requirement for CCN2 and TGF-β coadministration into the subcutaneous tissue to achieve sustained fibrosis ([@bib123]). However, genetic studies using both loss- and gain-of-function experiments in animals overexpressing active TGF-β did not support the notion that CCN2 plays an important role in TGF-β--driven fibrosis ([@bib3]).

Negative regulation of TGF-β signaling in fibrotic conditions {#s17}
-------------------------------------------------------------

Although activation of the TGF-β cascade is a critical component of the reparative response in many types of injury, tight regulation of TGF-β signaling is needed to protect the injured tissue from overactive fibrotic responses. Thus, chronic fibrotic conditions may, at least in some cases, reflect impaired endogenous negative regulation of TGF-β following injury. Signals that restrain TGF-β signaling may act at several different levels, by reducing binding of TGF-β to its receptors, by interfering with TβR/R-Smad interactions, by perturbing associations between R-Smads and Smad4, by enhancing degradation of TβRs or R-Smads, by dephosphorylating p-R-Smads, or by disrupting associations between the R-Smads and their transcriptional coactivators ([@bib78]).

The inhibitory Smads (I-Smads, Smad6 and Smad7) form a distinct subfamily of TGF-β--inducible Smads that antagonize TGF-β--mediated signaling ([@bib132]). Smad7 overexpression has been consistently found to attenuate fibrosis in many pathophysiologically distinct fibrotic conditions ([@bib133]) Several mechanisms have been suggested to explain the inhibitory actions of I-Smads. First, I-Smads may directly associate with TβRs, inhibiting TβRI kinase activity or interfering with TβR:R-Smad binding ([@bib80]; [@bib63]; [@bib118]). Second, I-Smads may form a complex with the inhibitory coreceptor BAMBI, inhibiting TβR-driven R-Smad activation ([@bib204]). Third, I-Smads may interact with the Smad ubiquitin regulatory factor (Smurf) 1 and Smurf2 type E3 ligases, promoting degradation of R-Smads ([@bib10]; [@bib130]). Fourth, I-Smads may interfere with formation of the complex between R-Smads and Smad4 ([@bib69]).

In addition to the effects of I-Smads, induced expression of inhibitory corepressors may contribute to negative regulation of TGF-β--mediated fibrosis. Recruitment of the transcriptional cofactors c-Ski (Sloan-Kettering Institute) and SnoN (Ski novel) may down-regulate TGF-β--driven fibrosis by repressing R-Smad--dependent transcription of fibrogenic genes ([@bib213]). In renal fibrosis, decreased expression of SnoN and c-Ski has been implicated in fibroblast activation ([@bib205]). Moreover, the nuclear receptor NR4A1 (nuclear receptor subfamily 4 group A member 1) was found to recruit a repressor complex, thus restraining fibrogenic TGF-β transcriptional responses in the skin and lung ([@bib139]).

It should be noted that many other signals may suppress TGF-β signaling through indirect actions, by interfering with pathways involved in TGF-β synthesis or modulating cascades that interact with the TGF-β/R-Smad axis. For example, the LIM domain protein LMO7 (LIM domain only 7) was found to restrain TGF-β--driven vascular fibrosis through interactions with the activator protein (AP)--1 transcription factor subunits c-FOS and c-JUN, ultimately disrupting AP-1--dependent TGF-β autoinduction ([@bib203]).

Targeting TGF-β cascades in fibrosis-associated pathological conditions {#s18}
-----------------------------------------------------------------------

Despite the extensive evidence suggesting a critical role for TGF-β cascades in tissue fibrosis, attempts to therapeutically target TGF-β in patients with fibrotic conditions have been challenging ([@bib70]). Clinical data on the efficacy of anti--TGF-β approaches in fibrosis-associated diseases are limited to early-phase trials with conflicting results ([Table 1](#tbl1){ref-type="table"}). Although a small clinical study suggested protective antifibrotic effects of broad TGF-β inhibition in patients with systemic sclerosis ([@bib150]), in other investigations, TGF-β1 neutralization failed to produce clinical benefit ([@bib36]). In many cases, underpowered study design limits conclusions regarding efficacy of TGF-β inhibition ([@bib186]). Adverse events were commonly noted ([@bib5]) but could not always be attributed to TGF-β neutralization.

###### Clinical studies targeting TGF-βs in specific fibrosis-associated conditions

  Disease                                            Strategy                                                                                                                                                                                                    Efficacy                                                                                                                                                                                                                                                               Adverse events                                                                                                                                                                                                                                                                                                                         References
  -------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------
  SSc                                                Patients with early-stage diffuse SSc (*n* = 45) were treated intravenously with the anti--TGF-β1 antibody CAT-192 (metelimumab) or placebo.                                                                No effect of anti--TGF-β1 treatment on cutaneous disease, assessed through the MRSS; TGF-β1 inhibition did not affect levels of circulating biomarkers of collagen metabolism.                                                                                         Adverse events (gastrointestinal, respiratory, and cutaneous) were frequent in both control and treatment groups. Although the incidence of adverse events and serious adverse events was higher in treated patients, this was considered consistent with the high morbidity of SSc and was not attributed to the use of medication.   [@bib36]
  SSc                                                Patients with early diffuse cutaneous SSc (*n* = 15) were treated with fresolimumab, a neutralizing antibody targeting all three TGF-β isoforms.                                                            TGF-β neutralization rapidly improved skin disease, decreasing MRSS. The clinical response was associated with attenuated expression of fibrosis-associated genes and reduced myofibroblast infiltration in the affected skin.                                         Bleeding episodes (gastrointestinal bleeding, epistaxis, gingival bleeding) and anemia (defined as a \>10% decrease in hemoglobin) were the most common adverse events in fresolimumab-treated patients.                                                                                                                               [@bib150]
  FSGS                                               In this phase I study, patients with treatment-resistant FSGS were treated with fresolimumab (single dose, *n* = 16).                                                                                       Proteinuria and other efficacy measures tended to fluctuate over the course of the study. There was no evidence of any treatment-related changes.                                                                                                                      A pustular rash was the most frequently reported treatment-emergent adverse event.                                                                                                                                                                                                                                                     [@bib180]
  FSGS                                               In this phase II double-blind study, patients with steroid-resistant FSGS were treated with fresolimumab or placebo (*n* = 36).                                                                             No significant effects of TGF-β inhibition. The absence of effects was attributed to underpowered design.                                                                                                                                                              Treatment-emergent adverse events (including rash, headache, and gingival bleeding) were noted in treated patients; however, overall fresolimumab was safe and well tolerated.                                                                                                                                                         [@bib186]
  Diabetic nephropathy                               Patients with advanced diabetic nephropathy were treated with a neutralizing anti--TGF-β1 antibody or placebo (*n* = 417).                                                                                  Early discontinuation due to lack of efficacy. Anti--TGF-β1 had no significant effects on renal function and did not affect proteinuria. Serum biomarkers reflecting matrix remodeling (fibronectin, high molecular weight collagen IV, and MMP7) were not affected.   Adverse events were common in both treated and untreated patients, reflecting the severity of underlying nephropathy; however, anti--TGF-β1 did not affect the incidence of adverse events.                                                                                                                                            [@bib188]
  Conjunctival scarring following glaucoma surgery   Patients undergoing trabeculectomy for glaucoma (*n* = 24) were treated with subconjunctival injections of lerdelimumab (CAT-152), an anti--TGF-β2 neutralizing antibody with cross-reactivity to TGF-β3.   Patients receiving CAT-152 had greater early reduction in intraocular pressure. The study may have been underpowered to detect differences in other endpoints.                                                                                                         No significant differences in the incidence of complications between groups.                                                                                                                                                                                                                                                           [@bib174]
  Conjunctival scarring                              Two randomized double-blind clinical trials examined the safety and efficacy of subconjunctival CAT-152 injection in patients undergoing trabeculectomy for uncontrolled glaucoma.                          There were no significant effects of TGF-β2 inhibition on surgical success.                                                                                                                                                                                            No significant adverse events could be attributed to local TGF-β inhibition.                                                                                                                                                                                                                                                           [@bib65]; [@bib87]

FSGS, focal segmental glomerulosclerosis; MRSS, modified Rodnan skin thickness score; SSc, systemic sclerosis.

Challenges in therapeutic translation of anti--TGF-β strategies in patients with fibrosis-associated conditions can be attributed to the broad biological effects of TGF-β and the complexity of fibrotic responses. First, the context-dependent actions of TGF-β, arising from interactions with numerous other pathways and distinct effects on various cell types, greatly complicate therapeutic approaches. Human conditions are complex and pathophysiologically heterogeneous; in many cases, fibrosis is only one of several cellular responses involved in organ dysfunction. Although TGF-β cascades are typically activated in fibrotic lesions, their functions are dependent on the cellular environment and the networks of interacting signals. Thus, the impact of TGF-β targeting in human patients with fibrosis-associated diseases may be difficult to predict on the basis of standardized animal models with much simpler and homogeneous pathophysiologic underpinnings. Second, activation of fibroblasts in fibrotic lesions is dependent on localized, spatially restricted activation of TGF-βs. Thus, global systemic TGF-β inhibition may not effectively target the fibrogenic environment, while exposing the patient to the perils of broad inhibition of homeostatic TGF-β responses. Approaches targeting integrin-dependent TGF-β activation may restrict inhibition of TGF-β responses to the fibrotic lesions ([@bib95]), thus improving efficacy and limiting adverse events. Third, the wide range of signaling cascades activated or modulated by TGF-βs broadens the impact of TGF-β inhibition approaches. Downstream TGF-β--activated signals with more specific fibrogenic functions need to be identified for therapeutic targeting. Fourth, fibrosis may in some cases represent a reparative or protective response. In organs lacking regenerative capacity, such as the heart, fibrotic remodeling may reflect activation of a reparative program to preserve structure and prevent adverse functional outcome in the presence of injury. In these cases, abrogation of TGF-β--driven protective and reparative signals could have catastrophic consequences ([@bib91]). Finally, the chronic nature of most fibrotic conditions may require prolonged targeting of the TGF-β system, increasing the risks for adverse events related to perturbed healing, vascular defects, immune system dysregulation, or tumorigenesis.

Conclusions {#s19}
===========

The complex biology of TGF-β poses significant challenges for clinical translation. Important questions remain to be answered. What is the primary stimulus for TGF-β activation in fibrotic conditions? What is the relative role of the three TGF-β isoforms in fibrogenic activation? Considering the complexity of TGF-β signaling responses, how does activation of specific TGF-β--driven cascades modulate fibroblast phenotype and function? What is the relative role of TGF-β actions on other cell types in fibrotic lesions? What are the main regulatory signals that restrain TGF-β signaling? What is the role of TGF-β signaling in human fibrotic diseases? Answering these questions is crucial to design therapeutic strategies targeting the TGF-β system in a wide range of fibrosis-associated diseases.
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